Medical Treatments for Prostate CancerThere are many different medical treatments for prostate cancer that involve the clinical care of a healthcare professional. These treatments include expectant therapy, surgery, radiation therapy, hormone therapy, and chemotherapy. Expectant therapy is to carefully observe and monitor the prostate cancer. Because prostate cancer cells often spread very slowly, many older men who have the disease may not need more extensive treatment. However, expectant therapy usually includes routine physician examinations, including digital rectal exams and PSA tests. The different types of surgery for prostate cancer are radical prostatectomy - an open-surgery procedure in which the entire prostate gland and surrounding tissue are removed. Transurethral resection of the prostate (TURP) - surgery to remove part of the prostate gland that surrounds the urethra. Cryosurgery - this procedure involves killing the cancer cells by freezing them with a small metal tool placed in the tumor. Side effects of prostate cancer surgery include incontinence and impotence. Incontinence is the inability to control urine and may result in dribbling of urine, especially immediately after surgery. Normal control usually returns within weeks or months after surgery. Impotence is the inability to achieve an erection. For a month, or so, after surgery, most men are not able to get an erection. Eventually, approximately 40 to 60 percent of men will be able to get an erection sufficient for sexual intercourse, but without ejaculation of semen, since removal of the prostate gland prevents that process.Radiation therapy uses high energy rays to kill or shrink cancer cells, and to decrease their ability to divide. Radiation is often used to treat prostate cancer that is still confined to the prostate gland, or has spread only to nearby tissue. If the disease is advanced, radiation may be used to reduce the size of the tumor and to provide relief from symptoms. Possible side effects of radiation for prostate cancer may include diarrhea, with or without blood in the stool, and colitis, problems associated with urination, a degree of impotence (inability to get an erection), which may occur within two years of radiation therapy. The goal of hormone therapy is to lower the level of male hormones in the body, particularly testosterone. Hormone therapy does not cure the cancer, and is often used to treat persons whose cancer has spread or recurred after treatment. Produced mainly in the testicles, testosterone causes prostate cancer cells to grow. Thus, reduced testosterone levels can make the prostate cancer shrink and become less active. Most studies show that hormone therapy works better if it is started early. Chemotherapy is the use of powerful, anti-cancer medications to kill cancer cells.. Hospitalization may be needed to monitor treatment and chemotherapy's side effects. Common side effects of chemotherapy include: nausea and vomiting, hair loss, anemia, reduced ability of blood to clot, mouth sores, increased likelihood of developing infections, fatigue. Most side effects disappear once treatment is stopped. |
| 17 aag prostate |
|
Sloan-Kettering - SPORE in Prostate Cancer: Therapy for Castration Our research is centered around developing a prostate cancer therapy that Conduct phase 2 clinical trials of the Hsp90 inhibitors 17-AAG or DMAG. The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent The Prostate DOI 10.1002/pros. Fig. 4. Effect of the hsp90 inhibitor 17-AAG on AR localization. and activity in androgen-refractory prostate cancer cells. Min,Y Yet, the (131)IIodo-17-AAG in the contralateral muscle was at a low Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. Thyroid cancer trial will test promising new drug called 17AAG 17AAG is currently in use in clinical trials against melanoma and ovarian, breast and prostate cancers, in addition to thyroid cancer. Alleviating Neurodegeneration by an Anticancer Agent: An Hsp90 The ability of 17-AAG to degrade mutant protein would be directly applicable to .. and HER-2/neu and inhibits the growth of prostate cancer xenografts. Phase 1 pharmacokinetic and pharmacodynamic trial of docetaxel and Three pts had stable disease of at least 3 cycles duration and one pt with prostate cancer had a decline in PSA. Plasma serum levels of docetaxel and 17AAG -- 95 (21): 1561 -- JNCI Journal of the National Cancer Institute Tomatoes, Lycopene, and Prostate Cancer in a Rat Model . To determine whether 17AAG leads to metabolic alterations that could serve as markers for tumor 17-AAG 17-AAG has been in clinical trials since 1999. It is now in phase II trials against melanoma, breast, prostate, and thyroid cancer. A phase II trial of 17-allylamino-17-demethoxygeldanamycin (17-AAG A phase II trial of 17-allylamino-17-demethoxygeldanamycin (17-AAG) in patients with hormone-refractory metastatic prostate cancer. E. I. Heath, D. Hillman, 17-AAG: mechanisms of antitumour activity 17-AAG caused growth inhibition in prostate, breast and ovarian mouse xenografts. in vivo. 3 . Multiple interacting signalling pathways are involved in 17AAG: Low Target Binding Affinity and Potent Cell Activity In tissue culture, we observe comparable activities against tumor and normal cells for GM and 17AAG. Primary prostate epithelial cells were treated with 17AAG: Low Target Binding Affinity and Potent Cell Activity normal cells for GM and 17AAG. Primary prostate epithelial. cells were treated with 17AAG or the synthetic inhibitors (Fig. CAT.INIST Prostate carcinoma cells were exposed either to 17-AAG alone or combined with a single radiation fraction of 3 Gy. Results: FAK concentrations were reduced National Prostate Cancer Coalition: Cancer Drug Targets "Heat National Prostate Cancer Coalition fights prostate cancer as your online source for Although 17-AAG is not Kosan's lead drug, it's a growing part of the A phase II trial of 17-allylamino-17-demethoxygeldanamycin (17-AAG A phase II trial of 17-allylamino-17-demethoxygeldanamycin (17-AAG) in patients with hormone-refractory metastatic prostate cancer. Hsp90 as a therapeutic target in prostate cancer. Prostate cancers are hormone-dependent malignancies that respond to drugs 17-Allyamino-17-demethoxygeldanamycin (17-AAG) is an inhibitor of the Hsp90 The Journal of Urology : Intratumor Injection of the Hsp90 Intratumor Injection of the Hsp90 Inhibitor 17AAG Decreases Tumor Growth and Induces Apoptosis in a Prostate Cancer Xenograft Model |
| 17 aag prostate |
|
dallas raines prostate cancer bob hunter prostate cancer cancer in lymph node prostate add information prostate site |